Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Itraconazole
Drug ID BADD_D01217
Description One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
Indications and Usage For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
Marketing Status approved; investigational
ATC Code J02AC02
DrugBank ID DB01167
KEGG ID D00350
MeSH ID D017964
PubChem ID 55283
TTD Drug ID D0V4IB
NDC Product Code 22568-1108; 53069-0450; 59349-0012; 65015-624; 65162-630; 60592-318; 62991-3078; 72761-019; 50268-450; 50458-290; 10147-0150; 67835-5043; 46708-204; 49884-239; 60687-299; 49452-3845; 51552-0920; 70771-1208; 17511-114; 71747-002; 13668-463; 67877-454; 12578-299; 38779-2759; 58032-0110; 66039-815; 62332-204; 65162-087; 69339-159; 10147-1700; 71052-301; 70518-2872; 70518-3559; 10695-064; 50546-462; 31722-006; 51862-462; 68382-697; 70518-3264; 66577-044; 16714-743; 16729-271; 50458-295
UNII 304NUG5GF4
Synonyms Itraconazole | R-51211 | R 51211 | R51211 | Sporanox | Orungal
Chemical Information
Molecular Formula C35H38Cl2N8O4
CAS Registry Number 84625-61-6
SMILES CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C 7=C(C=C(C=C7)Cl)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chronic obstructive pulmonary disease22.03.01.007--Not Available
Coagulopathy01.01.02.0010.005345%Not Available
Colitis07.08.01.0010.002672%
Condition aggravated08.01.03.0040.047300%Not Available
Confusional state17.02.03.005; 19.13.01.001--
Congenital anomaly03.02.01.001--Not Available
Constipation07.02.02.001--
Coordination abnormal17.02.02.0040.002672%Not Available
Cough22.02.03.0010.012025%
Cushing's syndrome19.07.03.002; 14.11.01.007; 05.01.01.001; 24.08.04.0010.013362%Not Available
Cushingoid24.08.02.004; 19.07.03.001; 14.11.01.006; 05.01.01.0020.002672%
Cutaneous vasculitis24.12.04.008; 23.06.02.001; 10.02.02.0030.002672%Not Available
Cystitis20.03.02.002; 11.01.14.001--
Cystitis haemorrhagic20.03.02.0030.002672%Not Available
Deafness04.02.01.001--Not Available
Dehydration14.05.05.001--
Delirium19.13.02.0010.004008%
Depression19.15.01.001--
Dermatitis23.03.04.0020.011224%Not Available
Dermatitis bullous23.03.01.0020.005345%
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Developmental delay19.07.05.003; 08.01.03.037--Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.0030.002672%Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.11.04.006--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.012025%Not Available
Drug ineffective08.06.01.0060.196147%Not Available
Drug interaction08.06.03.0010.151252%Not Available
Dysgeusia17.02.07.003; 07.14.03.001--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 12 Pages